Pharmafile Logo
Pharmafocus logo
Advanced Search

AstraZeneca

Showing 15 posts of 785 posts found.

astrazeneca-sign

AstraZeneca’s Imfinzi meets endpoint at Phase 3 interim analysis in extensive-stage small cell lung cancer

June 27, 2019
Research and Development AstraZeneca, Imfinzi, pharma

AstraZeneca has lifted the curtain on new Phase 3 data for Imfinzi (durvalumab) in the first-line treatment of extensive-stage small …

News
lynparza

EU approval for MSD and AZ’s Lynparza in first-line BRCA-mutated advanced ovarian cancer

June 18, 2019
Manufacturing and Production, Sales and Marketing AstraZeneca, Cancer, MSD, lynparza, ovarian cancer, pharma

AstraZeneca and MSD’s jointly-developed therapy Lynparza (olaparib) has scored its third EU approval, the pair announced, with authorisation for the …

News
cq5dam

AstraZeneca spends more than twice as much as expected on new HQ

June 12, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Cambridge, UK, headquarters, pascal soriot, pharma

AstraZeneca’s new headquarters in Cambridge, United Kingdom are expected to cost more than double the sum of £330 million that …

News
astrazeneca_building_white

AstraZeneca’s Phase 3 Farxiga data impresses in type 2 diabetes

June 11, 2019
Manufacturing and Production, Research and Development AstraZeneca, diabetes, farxiga, pharma, type 2 diabetes

AstraZeneca has presented new Phase 3 data at the American Diabetes Association (ADA) 79th Scientific Sessions in San Francisco on …

News
astrazeneca-sign

AstraZeneca’s Calquence shows strength in most common adult leukaemia

June 6, 2019
Research and Development AstraZeneca, Calquence, chronic lymphocytic leukaemia, pharma

AstraZeneca has unveiled new Phase 3 data for Calquence (acalabrutinib) in treatment-naïve chronic lymphocytic leukaemia, showing that the drug met …

News
astrazeneca-sign

AZ ends Calquence trial early after Phase 3 success in chronic lymphocytic leukaemia

May 8, 2019
Research and Development AstraZeneca, Calquence, pharma

AstraZeneca has unveiled new Phase 3 data on the efficacy of its Bruton tyrosine kinase (BTK) inhibitor Calquence (acalabrutinib) in …

News
credit_-_daniel_leal-olivas-afp

AZ and MSD’s Lynparza secures CHMP nod in first-line BRCA-mutated ovarian cancer

April 29, 2019
Sales and Marketing AstraZeneca, CHMP, Cancer, MSD, lynparza, ovarian cancer, pharma

AstraZeneca and MSD’s Lynparza (olaparib) has received a positive opinion from the EMA’s Committee for Medicinal Products for Human Use …

News
lynparza

Europe approves Lynparza in HER2-, gBRCAm advanced breast cancer

April 10, 2019
Research and Development, Sales and Marketing AstraZeneca, Cancer, MSD, breast cancer, lynparza, pharma

Lynparza (olparib), the poly ADP ribose polymerase (PARP) inhibitor developed by AstraZeneca and MSD, has been awarded marketing approval by …

News
top_10_image

Top Ten most popular articles on Pharmafile.com this week!

April 5, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, AstraZeneca, Northern Ireland, Novartis, Placebo, UK, brexit, pharma

As Brexit looms, pharma trade lobby the ABPI called for a ban on exports of medicines in the case of …

News
astrazeneca-sign

AstraZeneca’s early-stage Fasenra study smashes primary endpoint in hypereosinophilic syndrome

April 4, 2019
Research and Development AstraZeneca, Fasenra, hypereosinophilic syndrome, pharma

AstraZeneca has revealed new data for Fasenra (benralizumab), demonstrating that patients using the drug can “achieve near-complete depletion of eosinophils …

News
shutterstock_273326141

AstraZeneca and Daiichi Sankyo partner up for $6.9 billion cancer collaboration

March 29, 2019
Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Cancer, Daiichi Sankyo, pharma

AstraZeneca and Daiichi Sankyo have announced a new collaboration agreement to the tune of potentially $6.9 billion which will see …

News

AstraZeneca’s Imfinzi to be made available via Cancer Drugs Fund in England

March 28, 2019
Sales and Marketing AstraZeneca, Cancer, Imfinzi, NHS, NICE, UK, lung cancer

AstraZeneca’s PD-L1 inhibitor Imfinzi (durvalumab) will now be made available to English lung cancer patients on the NHS via the …

News
astrazeneca_building_white

AZ’s diabetes drug Forxiga secures EU approval for adjunctive use in type 1 patients

March 25, 2019
Sales and Marketing AstraZeneca, Forxiga, diabetes, pharma

AstraZeneca has revealed that its sodium-glucose co-transporter 2 (SGLT2) inhibitor Forxiga (dapagliflozin) has secured approval from the European Commission for …

News
top_10_image

Top Ten most popular articles on Pharmafile.com this week!

March 22, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Biogen, Eisai, FDA, Merck, NICE, Pfizer, Roche, Sandoz

This week was a bad week for clinical trials. While the FDA put Roche and AbbVie’s multiple myeloma trial on …

News
astrazeneca_plaque

AZ’s Farxiga reduces major adverse cardiovascular event risk in type 2 diabetes, new data shows

March 19, 2019
Manufacturing and Production, Research and Development AstraZeneca, cardiovascular, farxiga, pharma

AstraZeneca has lifted the curtain on new Phase 3 data for its sodium-glucose co-transporter 2 (SGLT2) inhibitor Farxiga (dapagliflozin), reinforcing …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026